Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | PBRM1 |
Variant | W141_L145delinsC |
Impact List | indel |
Protein Effect | unknown |
Gene Variant Descriptions | PBRM1 W141_L145delinsC results in a deletion of five amino acids of the Pbrm1 protein from amino acids 141 to 145, combined with the insertion of a cysteine (C) at the same site (UniProt.org). W141_L145delinsC has been identified in the scientific literature (PMID: 29301960), but has not been biochemically characterized and therefore, its effect on Pbrm1 protein function is unknown (PubMed, Nov 2022). |
Associated Drug Resistance | |
Category Variants Paths |
PBRM1 mutant PBRM1 W141_L145delinsC |
Transcript | NM_018313.4 |
gDNA | chr3:g.52662227_52662238del12 |
cDNA | c.423_434del12 |
Protein | p.W141_L145delinsC |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_018313 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006758.1 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
NM_181042.4 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_005265282.4 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_005265280 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006746.2 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006757 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006749 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006746 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006737 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006738 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006748 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006758 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
NM_018313.4 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006748.1 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006750 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_005265279 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006745.2 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006765 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_005265282 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006738.2 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006737.1 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_005265279.5 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006740 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006745 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006739.1 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
NM_001350075.1 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006749.1 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006750.1 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006739 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_005265283 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_005265280.3 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
XM_017006740.1 | chr3:g.52662227_52662238del12 | c.423_434del12 | p.W141_L145delinsC | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PBRM1 W141_L145delinsC | clear cell renal cell carcinoma | no benefit | Nivolumab | Case Reports/Case Series | Actionable | In a clinical study, Opdivo (nivolumab) treatment resulted in progressive disease in a patient with renal clear cell carcinoma harboring PBRM1 W141_L145delinsC (PMID: 29301960). | 29301960 |